Hara Capital LLC Acquires Shares of 160 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hara Capital LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 160 shares of the biopharmaceutical company’s stock, valued at approximately $168,000.

Several other hedge funds also recently made changes to their positions in REGN. Principal Financial Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock valued at $181,961,000 after buying an additional 2,828 shares during the period. Montecito Bank & Trust lifted its holdings in Regeneron Pharmaceuticals by 89.5% in the third quarter. Montecito Bank & Trust now owns 1,114 shares of the biopharmaceutical company’s stock worth $1,171,000 after acquiring an additional 526 shares during the last quarter. Graypoint LLC boosted its stake in Regeneron Pharmaceuticals by 3.3% in the third quarter. Graypoint LLC now owns 2,346 shares of the biopharmaceutical company’s stock valued at $2,466,000 after acquiring an additional 76 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the third quarter. Concurrent Investment Advisors LLC now owns 861 shares of the biopharmaceutical company’s stock valued at $906,000 after purchasing an additional 30 shares during the last quarter. Finally, Umpqua Bank raised its position in shares of Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. Umpqua Bank now owns 1,426 shares of the biopharmaceutical company’s stock worth $1,499,000 after purchasing an additional 32 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of REGN stock traded up $4.40 during trading hours on Thursday, reaching $821.05. 88,270 shares of the stock traded hands, compared to its average volume of 518,912. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $90.51 billion, a PE ratio of 20.21, a PEG ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 1-year low of $783.57 and a 1-year high of $1,211.20. The business has a fifty day moving average price of $1,035.92 and a 200 day moving average price of $1,038.36.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Oppenheimer reduced their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. BMO Capital Markets dropped their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Guggenheim raised their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Barclays reduced their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. One analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $1,092.62.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.